Oxygen Vacancy-Reinforced Water-Assisted Proton Hopping for Enhanced Catalytic Hydrogenation

Water-assisted proton hopping (WAPH) has been intensively investigated for promoting the performance of metal oxide-supported catalysts for hydrogenation. However, the effects of the structure of the metal oxide support on WAPH have received little attention. Herein, we construct oxygen vacancy-bearing, MoO3–x-supported Pd nanoparticle catalysts (Pd/MoO3–x-R), where the oxygen vacancies can promote WAPH, thereby facilitating catalytic hydrogenation. The experimental results and theoretical calculations show that the oxygen vacancies favor the adsorption of water, which assists the proton hopping across the surface of the metal oxide, enhancing the catalytic hydrogenation. Our finding will provide a potential approach to the design of metal oxide-supported catalysts for hydrogenation

Additional file 2: Table S1. of An analysis of 97 previously diagnosed de novo adult acute erythroid leukemia patients following the 2016 revision to World Health Organization classification

The ratio of different cytogenetic risk category in different age group. The ratio of different cytogenetic risk category (intermediate and unfavorable risk) in <40, 40–60, >60 age group. (DOCX 12 kb

Additional file 1: Figure S1. of An analysis of 97 previously diagnosed de novo adult acute erythroid leukemia patients following the 2016 revision to World Health Organization classification

The 3-year OS of 97 previously diagnosed de novo adult AEL patients according to age group. The 3-year OS of <40, 40–60 and >60 age group. (TIFF 170 kb

The number of CD34+CD38+CD117+HLA-DR+CD13+CD33+ cells indicates post-chemotherapy hematopoietic recovery in patients with acute myeloid leukemia

<div><p>Hematopoietic recovery is considered to be associated with the number of multipotent hematopoietic stem cells in the bone marrow, as observed in functional assays involving stem cell transplantation. However, there is little evidence related to hematopoietic recovery in non-transplantation settings, which is accomplished by endogenous hematopoietic cells. A recent study suggested that progenitors are the main contributors during this steady-state hematopoiesis, which differs from exogenous transplantation. We hypothesized that endogenous progenitor support post-chemotherapy hematopoietic recovery. To investigate the potential impact of these progenitor cell percentage on hematopoietic recovery, we retrospectively analyzed the percentage of CD34+CD38+CD117+HLA-DR+CD13+CD33+ cells (P cells) and hematopoietic recovery in 223 newly diagnosed acute myeloid leukemia patients during two courses of consolidation chemotherapy after complete remission. We found that a lower P cell percentage was significantly associated with prolonged neutropenia recovery time after the first and second courses of consolidation chemotherapy (p = 0.001; p = 0.045, respectively). We also observed similar results with regard to platelet recovery time after the first course of consolidation chemotherapy (p = 0.000). Univariate analysis showed that P cell percentage and consolidation chemotherapy regimens, and not gender, age, induction chemotherapy regimens, infection grade, WHO classification and NCCN risk category, were associated with neutrophil recovery after chemotherapy. Multivariate analysis demonstrated that P cell percentage is an independent factor affecting neutrophil recovery capacity for both the first and second courses (p = 0.008; p = 0.032, respectively). Our results indicate that CD34+CD38+CD117+HLA-DR+CD13+CD33+ cells before each course of chemotherapy is independently associated with chemotherapy-related hematopoietic reconstitution capacity. These findings may help modify future chemotherapy regimens based on progenitor cell percentages.</p></div

Additional file 3: of An analysis of 97 previously diagnosed de novo adult acute erythroid leukemia patients following the 2016 revision to World Health Organization classification

Raw data. The clinical characteristic of 97 previously diagnosed de novo adult acute erythroid leukemia patients. The clinical characteristic of 97 previously diagnosed de novo adult acute erythroid leukemia patients were listed, including MDS/AML subtype, MRC cytogenetic risk, survival data, gene mutation and so on. (DOC 239 kb

Additional file 1: of Distinct genetic alteration profiles of acute myeloid leukemia between Caucasian and Eastern Asian population

This file contains Tables S1–S7, including Table S1. CBF ratios in European, American, and Eastern Asian cohorts; Table S2. NPM1 mutation ratios in European and our cohorts; Table S3. FLT3-ITD mutation ratios in European and our cohorts; Table S4. FLT3-ITD mutation ratios in older patients from Chinese cohort against European and American cohorts; Table S5. CBF leukemia ratios in older patients from Japanese and Chinese cohorts against European and American cohorts; Table S6. NPM1 mutation ratios in older patients from Chinese cohort against European and American cohorts; and Table S7. Outcomes in European, American, and Eastern Asian cohorts. (PDF 568 kb

Multivariate analysis for ANC recovery in consolidation one.

<p>Multivariate analysis for ANC recovery in consolidation one.</p

Univariate analysis for ANC recovery.

<p>Univariate analysis for ANC recovery.</p

Multivariate analysis for ANC recovery in consolidation two.

<p>Multivariate analysis for ANC recovery in consolidation two.</p

Patients with higher P cell percentages possess better hematopoietic recovery.

<p>Evaluation of hematopoietic recovery in patients with different pre-chemotherapy P cell percentages (Q1groupor Q2-4 group) after consolidation chemotherapy. Times of neutropenia after the first (A) and the second (B) courses of chemotherapy were evaluated, as well as platelet (PLT) recovery time (C and D), G-CSF levels (E andF) and platelet transfusion amount (G and H). The data are shown as the means±SEM of the indicated number of patients.</p